Biobridge Partners

𝗪𝗲𝗹𝗰𝗼𝗺𝗲, 𝗔𝗿𝗶𝗮! 🚀 We’re delighted to welcome Aria Shahzadi as the latest addition to our growing team at Biobridge Partners! With over a decade of experience in management consulting at the intersection of commercial excellence, strategy, and life sciences, Aria joins us as a Principal. Prior to joining Biobridge Partners, Aria worked at Simon-Kucher & Partners in the Life Science division where he advised pharmaceutical manufacturers, medtech/healthtech firms, and healthcare investors on growth, pricing, and commercial excellence. Since then, Aria has also worked with start-ups, venture funds, and family offices in the Nordics to drive profitable growth strategies for healthcare start-up firms. His unique blend of expertise across both established firms and innovative start-ups will make him an invaluable asset to our team. Please join us in giving Aria a warm welcome! We’re excited to have you onboard! #teamexpansion #curiousthinkers #strategyconsulting

This week, I had the pleasure of attending a fascinating panel discussion on AI for drug discovery alongside industry experts Jonathan Ilicki, Julie Klint, and Hisham Hamadeh, with Paul Ainsworth moderating the discussion. The session touched on some critical challenges and opportunities AI brings to the pharma and biotech sectors. One key topic we explored was the barriers pharma and biotech companies need to overcome to fully harness the value of AI. For established pharma companies, a major challenge is building a solid data and technology infrastructure. But just as important are the softer aspects: developing new capabilities, fostering innovative ways of working, and cultivating a data-driven culture. Achieving this transformation requires a clear, compelling vision, visible leadership, and strategic direction that is understood and embraced across the organization. For smaller, pre-clinical biotech companies, navigating the AI landscape can feel overwhelming. The distinction between value and hype often appear unclear. A crucial first step is identifying where and how AI can create value within the research pipeline. At Biobridge Partners, we will soon be releasing our perspective on how biotech companies can embark on this AI journey. If you'd like to receive a copy of the report, feel free to reach out to me. Many thanks to the rest of the panel and to LSX Nordic Congress for facilitating these insightful discussions!

𝗠𝗲𝗲𝘁 𝘂𝘀 𝗮𝘁 𝗟𝗦𝗫 𝗡𝗼𝗿𝗱𝗶𝗰 𝟮𝟬𝟮𝟰! 👋 We are excited to share that Biobridge Partners will be attending the LSX Nordic Congress in Copenhagen this year! Our very own Daniel will be joining an expert panel discussion on 𝘈𝘐 – 𝘈 𝘎𝘢𝘮𝘦 𝘊𝘩𝘢𝘯𝘨𝘦𝘳 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘍𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘕𝘰𝘳𝘥𝘪𝘤 𝘓𝘪𝘧𝘦 𝘚𝘤𝘪𝘦𝘯𝘤𝘦𝘴. Together with Paul Ainsworth (Sterne, Kessler, Goldstein & Fox), Hisham Hamadeh (Genmab), Jonathan Ilicki (Industrifonden), and Julie Klint (Lundbeck), they will discuss how AI is changing drug discovery and increasing R&D productivity, but also what challenges are associated with the implementation. 📅 𝗣𝗮𝗻𝗲𝗹 𝗗𝗮𝘁𝗲 & 𝗧𝗶𝗺𝗲: 08 October, 13:50 📍 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: LSX Nordic Congress, Copenhagen We also invite you to visit our booth and meet Jonas and Emma, who will be on hand to discuss strategy, innovation, and the future of life sciences with you. Whether you want to explore new ideas or network with industry peers, we’d love to connect! See you in Copenhagen! #LSXNordic #AI #lifescience LSX - partnering for Life Science eXecutives

𝗧𝗮𝗸𝗲-𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗗𝗮𝗻𝗶𝘀𝗵 𝗕𝗜𝗢 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 🤖 Biobridge Partners had the privilege of attending this year’s Danish BIO Annual Meeting, where the biotech ecosystem came together for insightful discussions on adopting AI in biotechnology. Our own Emma Jappe Lange presented the results of our Nordic assessment of AI maturity among biotechs and facilitated an engaging panel discussion with industry leaders: Martin S. Borchert (Novonesis), Nabiha Saklayen (Cellino), and Roald Forsberg (Raven biosciences). Three takeaways that stood out to us were: 🌱 𝗔𝗜 𝗰𝗮𝗻 𝗰𝗿𝗲𝗮𝘁𝗲 𝘃𝗮𝗹𝘂𝗲 𝗳𝗼𝗿 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗼𝗳 𝗮𝗹𝗹 𝘀𝗶𝘇𝗲𝘀: Being a small biotech with a greenfield approach can actually be a competitive advantage. AI is not just for large companies—nimble startups can quickly adopt AI solutions and innovate faster by leveraging the ecosystem. 🚀 𝗬𝗼𝘂 𝗱𝗼𝗻’𝘁 𝗵𝗮𝘃𝗲 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝗮𝘀 𝗮𝗻 𝗔𝗜 𝗰𝗼𝗺𝗽𝗮𝗻𝘆: Biotech companies can leverage advanced models and tools developed by big tech companies. By combining these with proprietary data and models, companies can create something uniquely valuable and competitive in the market. ✨ 𝗜𝘁’𝘀 𝗢𝗞 𝘁𝗼 𝗳𝗮𝗶𝗹: A key takeaway was the need for a mindset shift within the Nordic biotech ecosystem. Embracing a risk-taking, fail-fast mentality similar to that of the U.S. can accelerate innovation. Failures should be celebrated as learning experiences that often lead to breakthroughs down the line. Thank you to DANISH BIO - DANSK BIOTEK and Gorrissen Federspiel for hosting a fantastic event! #AI #biotech #lifescience

Unlocking AI in Biotech: AI and Big Data at the Danish BIO Annual Meeting! We’re excited to join the upcoming DANISH BIO - DANSK BIOTEK Annual Meeting, where the spotlight will be on the transformative role of AI and Big Data in biotech. 🔬🧬🤖 Our very own Emma Jappe will present key findings from Biobridge Partners’ recent AI readiness assessment among Nordic biotech companies and moderate a roundtable discussion on the state of AI in the Nordics. This is an invaluable opportunity to network with biotech leaders, reconnect with clients and partners, and gain actionable insights into the future of biotech and AI innovation. 🔗 Interested in joining? Register today via the link in the image below! #AIinBiotech #DanishBIO #BigData #LifeSciencesInnovation #Networking

𝗖𝗼𝗽𝗲𝗻𝗵𝗮𝗴𝗲𝗻-𝗯𝗮𝘀𝗲𝗱, 𝗴𝗹𝗼𝗯𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 🌍 Jonas and Florian from the Biobridge Partners team are on their way back to Copenhagen after a few successful days in Zurich. Engaging with clients in workshops and beyond, it’s been a productive trip, full of insights and collaboration. While we're based in Copenhagen, our impact continues to be global. Exciting times ahead! #globalimpact #lifescience

𝐁𝐢𝐨𝐛𝐫𝐢𝐝𝐠𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐧𝐞𝐰𝐬 📰 In case you missed it: Earlier this month, we welcomed Jens Rommer, former head of Deloitte’s strategy unit, to the Biobridge Partners team. Jens will play a pivotal role in scaling our business and helping us drive meaningful impact in the life sciences sector, both in Denmark and abroad. In this InsideBusiness article, Nicolai Hesdorf, our Chair of the Board, Jens, and other industry players share their perspective on Biobridge Partners' future, and how the strategy consulting industry is changing. Don’t miss their insights - link in the comments (in Danish). #strategy #lifesciences #growth

𝐍𝐨𝐭 𝐨𝐧𝐞, 𝐧𝐨𝐭 𝐭𝐰𝐨, 𝐛𝐮𝐭 𝐓𝐇𝐑𝐄𝐄 𝐧𝐞𝐰 𝐂𝐮𝐫𝐢𝐨𝐮𝐬 𝐓𝐡𝐢𝐧𝐤𝐞𝐫𝐬 🚀 We are excited to welcome Jens Rommer, Lea Dissing, and Amadou Benavent to Biobridge Partners. Each brings a wealth of experience, deep expertise, and a shared passion for life sciences. Let's get to know them a bit better: Jens joins us as Partner, bringing nearly 30 years of strategy and management consulting experience. He most recently led Monitor Deloitte's strategy practice in Denmark, where he worked with leading global organisations on strategic problem-solving and transformational initiatives. Jens is a seasoned expert in guiding senior executives through their most critical growth challenges, leveraging new technology solutions, and designing growth-oriented operating models. Lea joins us as our People Lead, driven by a genuine passion for enhancing the employee experience at Biobridge Partners. With extensive HR leadership experience in both startup and scale-up environments, Lea’s focus will be to attract, develop, and retain the best people in the industry. Lea will play a crucial role in ensuring that Biobridge Partners remains a place where talent can truly flourish. Amadou rejoins us as Consultant, bringing a unique blend of biotechnological research and business administration expertise. During his previous internship at Biobridge Partners, he explored AI adoption in Nordic biotechs, particularly in early drug discovery. Amadou’s positive energy and collaborative spirit, combined with his drive and curiosity, make him an ideal fit for our team. Please join us in welcoming Jens, Lea, and Amadou to the Biobridge team! We are excited to see the impact they will make as we continue to strengthen our practice and take lead in life sciences consulting. #lifesciences #growth #curiousthinkers

Biobridge summer update ☀️ As the Biobridge Partners team heads off for a well-deserved summer vacation, we closed the first half of 2024 with our annual summer party. We started with a kayak tour, helping to keep Copenhagen’s canals clean, followed by some good food and karaoke. 🎤 This year, the summer break also meant saying goodbye to our beloved offices on Gammel Kongevej with its beautiful lake view. At the same time, we're excited to announce our relocation to Symbion Community’s new life science hub in Fuglebakken, offering us more space to grow within an innovative ecosystem. More details to come soon! We wish all our clients and friends of Biobridge a wonderful summer – see you on the other side! 🏖️

Driving innovation with purpose: The Biobridge 20% 🚀 At Biobridge Partners, we're proud of our commitment to dedicating 20% of our time to activities that prioritise innovation and impact over commercial interest. The "Biobridge 20%" – anchored in our articles of association – reflect our dedication to advancing cutting-edge biotech and health innovations that address unmet needs. Here are three impactful projects we've delivered over the past year: 🧭 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐫𝐨𝐚𝐝𝐦𝐚𝐩 𝐟𝐨𝐫 𝐩𝐫𝐞-𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 We evaluated the strategy of a pre-clinical product for a biotech company and delivered a clear roadmap towards successful commercialisation. 🧫 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐥𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲 Our team defined an operating model and explored business model opportunities to support sustainable operations for a state-of-the-art cell therapy development facility. 🔬 𝐄𝐚𝐫𝐥𝐲 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐟𝐨𝐫 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 We facilitated an early commercial strategy process for a biotech’s metabolomics platform, assessing the implications for its development strategy and developing an implementation roadmap. If you have a project that you think could qualify based on its potential for making a significant positive impact on society via life sciences, we would love to talk! 💚 #lifesciences #innovation #impact